Edwards Plans $76 Million Expansion Of Singapore Heart-Valve Facility
This article was originally published in PharmAsia News
Executive Summary
Edwards Lifesciences said it is expanding a manufacturing facility In Singapore to produce tissue for artificial heart valves, increasing its investment in the country to.$76 million over the past eight years.